Nurix Therapeutics Inc
NRIX
Market Cap$1.43B
Close$
Share Statistics
| Market cap | $1.43 Billion |
|---|---|
| Enterprise Value | $1.43 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.65 |
| Beta | 2.22 |
| Outstanding Shares | 62,377,551 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -8.39 |
|---|---|
| PEG | 345.52 |
| Price to Sales | 9.12 |
| Price to Book Ratio | 1.3 |
| Enterprise Value to Revenue | 16.12 |
| Enterprise Value to EBIT | -6.18 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.18 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Nurix Therapeutics Inc
2,020 employeesNurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other ch...